Pharmaceuticals

Is ENVB a trending stock, the best stock to buy? Urgent Update

Is ENVB the best stock to buy because it has been breaking it’s trend with large volume and a 8% change in PPS in 5 days. Is it considered aa trending stock? Wondering why this stock is taking off, take a look below.

Before we do, remember to stop what you are doing and 👇 sign up for our newsletter below. 👇


[thrive_leads id=’14274′]

Before we get started, I wanted to introduce myself to you. Hi 🙋‍♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.

I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.

What do I mean by big winners?

Stocks that move more than 100% in a month! ENVB Stock Price could?

Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!

The article is HERE where I shine a spotlight on trending stocks and breakout stocks!

Now, let’s go over if AXAS is the best stock to buy and if it is a trending stock? Below, is some of the basic information on this stock before we get in the technical analysis

Enveric Biosciences Company Information

Company Name: Enveric Biosciences Inc.

Ticker: ENVB

Exchange: NASDAQ

Website: https://www.enveric.com/

Enveric is developing new and improved medicines to treat physical and mental ailments stemming from cancer and other conditions. Our mission is to improve the characteristics of psychedelic- and cannabinoid-derived pharmaceuticals by unlocking their full potential to create treatment solutions for a variety of indications with serious unmet medical needs.

Is ENVB the best stock to buy, let’s look at the news

March 1, 2022

Announced that it has filed its 10th Patent Cooperation Treaty (“PCT”) patent application directed to tryptamine-based derivative molecules, completing the Company’s broad series of PCT applications covering this family of compounds.

ENVB 5 Day Chart

trending stock

Enveric Biosciences Technical Analysis, is it the best stock to buy:

First off, it is a trending stock because the news above is solid! Also, they did a public offering to the tune of $10 Million late last month. The real question is, is it the best stock to buy?

I don’t think it is but it is a solid option that appears to be setting up nicely for a bullish move soon.

#1 thing I like about it, it’s a huge bounce play with an upside of 100%

#2 thing I like about it it, it is trending bullish with good news

I hope I did a good job with my analysis of ENVB and if it is the best stock to buy?

This is Alex, reminding all the traders out there to leave your emotions at the door and never, ever, try to catch a falling knife. I strive to find breakout stock alerts and deliver them before the market finds out. I sure hope you enjoyed this article, if you would like to receive more exclusive content from me 👇 sign up for our newsletter below. 👇


[thrive_leads id=’14274′]

read more
Meso Numismatics (MSSV) skyrocketing

Meso Numismatics (MSSV) skyrocketing

Meso Numismatics (MSSV) up over 200% in a week

Company Name: Meso Numismatics (MSSV)

Ticker: MSSV

Exchange: OTC Website: www.stemcellsgroup.com

Company Summary:

Meso Numismatics, Inc. acquired Global Stem Cells Group (Global) is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training.

Global licenses its intellectual property and name to medical professionals around the world providing them with necessary equipment and cellular therapy products needed to perform safe and effective Regenerative Medicine related treatments.

Global has one of the largest physician membership networks in the world with 29 offices in more than 25 countries.

Why did it go up over 200%?

There is no news out or press releases. It appears to be an awareness campaign. I do find Meso Numismatics acquisition of Global Stem Cells Group (Global) four months ago as a good omen. Global is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training.

Meso Numismatics (MSSV) 5 Day Chart

Meso Numismatics (MSSV) technical analysis shows there is resistance at $.33 & $.345, be sure to break through those resistance points before considering a purchase.
MSSV is trending bullish in the 5 day chart and month chart but is showing bearish tendencies in the one day chart. There is thin volume on this stock so be aware of that as you proceed.

read more
UPDATE:! 100% Correct, Alex made 5 correct predictions for Petros Pharmaceuticals, Inc. PTPI!

UPDATE:! 100% Correct, Alex made 5 correct predictions for Petros Pharmaceuticals, Inc. PTPI!

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why is it red HOT?

Petros  reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. 

What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make 

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

Alex wrote on Monday 12/13/21 a 5 Day Technical Analysis based on this chart below:

The Predictions

“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s take a close look at the 1 day.” “It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?”

Let’s look at each prediction 

Prediction #1  “about to go bearish”

“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish “It’s very simple, can it beat $4.38? If it can’t, I would expect a pullback then consolidation and then a run!

Let’s look at where it is around lunch on Wednesday 12/15/21

WOW Alex called prediction 1 with a 38% pullback

Prediction #2 I would expect a pullback then consolidation

“If it can’t, I would expect a pullback then consolidation and then a run!” You can see in the above chart the consolidation call! This is not fortune telling, the chart is like a book and if you know how to read the language it is written in, it makes total sense!

As you can see from the above chart it most definitely consolidated. Let’s see what happened after consolidation!

Alex Goldman Prediction #3: RUN

I would expect a pullback then consolidation and then a run!

As you can see from the above chart it ran MINUTES after the article was finished and gave our subscribers a chance at 28% & 43% RUNS

Alex Goldman Prediction #4: “It is about to run”

Alex wrote a follow up Article HERE Wednesday last week Dated 12/15/21 updating our subscribers

Alex wrote on midday Wednesday 12/15  “It is about to run! It is bullish and I like it! Put it on your watchlist and Let’s make some money!!!!”

Alex Goldman Prediction #5: “SCALP”

wait for confirmation of a reversal and get ready for a quick scalp.

Alerted our EXCLUSIVE subscribers via email yesterday 12/20/21.

You can sign up below

Alex wrote in the email on Monday 12/20  “It is now in a bearish trend for the 1 day but still bullish overall. My recommendation is to wait for confirmation of a reversal and get ready for a quick scalp.

SCREENSHOT PROOF FROM OUR EMAIL HERE

OK it is official, Alex really really knows the movement and nuances of this chart! He called yet another massive gain today at 49%

What is Alex’s next prediction for PTPI?

Sign up for our newsletter below, IT’S FREE and you could win $250!

read more
UPDATE: Alex believes Petros Pharma (PTPI) is ready to BOUNCE, PAY ATTENTION!

UPDATE: Alex believes Petros Pharma (PTPI) is ready to BOUNCE, PAY ATTENTION!

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why did it go up over 100%?

reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.

“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make 

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.

I wrote on Monday 12/13/21 a 5 Day Technical Analysis:

“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s take a close look at the 1 day.”

Yes, I was right it went BEARISH!

I wrote on Monday 12/13/21 a 1 Day Technical Analysis:

“It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?”

Let’s look at where it is around lunch on Wednesday 12/15/21

WOW I called it, it didn’t break $4.38 and it did PULLBACK 38%! 

Called it AGAIN, Now it is consolidating!

Alex Goldman Prediction:

It is about to run! It is bullish and I like it! Put it on your watchlist and Let’s make some money!!!!

read more
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

Company Name: BELLUS Health Inc. 

Ticker: (BLU)

Exchange: NASDAQ

Website:  www.bellushealth.com

Company Summary:

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC and is planning a Phase 3 program that is expected to begin in 2022.

Why did it go up almost 100%?

Link HERE – LAVAL, Quebec, December 13, 2021–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related adverse events reported (≤6.5%) at all doses.

Mr. Roberto Bellini, Chief Executive Officer of BELLUS Health commented, “We are extremely pleased with the compelling topline results from the Phase 2b SOOTHE trial which highlight BLU-5937’s best-in-class potential for the treatment of refractory chronic cough. RCC is a prevalent and growing condition that significantly impacts the quality of life of an estimated 9 million patients in the United States and 9 million patients in Europe.”

5 Day Technical Analysis:

There are a lot of traders at $9.05, so if this stock can beat $9.05 tomorrow, I like it. If not, and I’m thinking it won’t, stay away. Caveat, the news is really good, so I hold out hope, but I don’t like the huge 70% gap up. Happy trading and always play it safe with trailing stops!

read more
Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?

Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Exchange: NASDAQ

Website: https://STENDRA.com/.

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why did it go up over 100%?

Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today reports positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.

“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the United States. While the process of gathering data to be shared with the U.S. Food and Drug Administration (FDA) continues, we are enthusiastic about our progress toward providing new hope for the millions of men suffering from this condition,” commented Fady Boctor, Petros’s President and Chief Commercial Officer.

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.

5 Day Technical Analysis:

It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s tak a close look at the 1 day.

1 Day CHart Technical Analysis

It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?

read more
Do We Use Crystal Balls? Two Winners and Three Losers

Do We Use Crystal Balls? Two Winners and Three Losers

Loser #1:

Company Name: Auri, Inc.

Ticker: AURI

Exchange: OTC

Website: www.auri.club

Company Summary:

Auri provide a wide range of services such as software solutions, e-commerce, and information technology

Why did it go up over 100%?

Dec. 8, 2021 

Auri announced plans to provide a wide range of services such as software solutions, e-commerce, and information technology.

Aurium app (www.auri.club)

Our Crypto Trading App will offer anonymity, Fiat support, unlimited purchases, and the purchase of rare tokens, which are not available on exchanges.

Auri token

The company will launch its own Crypto Currency, in order to enhance the shareholders’ value and participate in Digital and Crypto Currencies buy, sell and trade markets.

1 Day Chart

Technical Analysis:

The stock hasn’t traded in almost six months and every time this ticker moves it pulls back. It raades the majority of the time around $.004 and I forecast it will return to this PPS within a month. Until this stock proves it has steady substantial news with sustained runs, I’m a skeptic. 

Loser #2:

Company Name: EHAVE

Ticker: EHVVF

Exchange: OTC

Website: www.PSLY.COM

Company Summary:

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology.

Why did it go up over 100%?

12/8/21

EHAVE plans to explore a merger and the formation of PSLY.COM, a $360 Million transaction, and will apply to list shares on NASDAQ; Ehave plans to spin out 30%

1 Day Chart

Technical Analysis:

The news was weak, it’s an LOI (letter of intent) and the technicals are not much better. If it can break $.02 tomorrow, I would change my mind but the chart predicts a price reduction due to the bearish channel. 

Loser #3:

Company Name: Cuba Energy

Ticker: CUBV

Exchange: OTC

Website: https://www.cubenergyinc.com/

Company Summary:

Cub Energy has 311,000 gross acres (142,000 net) in two prospective basins in Ukraine. Ukraine has an attractive pricing environment for natural gas and power.

The Company is focused on growing its energy business in Ukraine. Cub aims to develop this asset portfolio to take advantage of attractive commodity prices. Cub is also focused on de-risking of its assets through the use of western methods and technologies.

Why did it go up over 100%?

No news, so I will assume this is a paid campaign. This stock has been promoted several times and it a story as old as time, what goes up must come down, really down!

5 Day Chart

Technical Analysis:

It’s a stinker, stay away! The intraday trend is bearish, the long term trend is bearish, this stock is and has always been bearish.

Winner #1:

Company Name: One World Universe Inc

Ticker: OWUV

Exchange: OTC

Website: https://oneworlduniverseinc.com/ (under construction)

Company Summary:

One World invests in sports related businesses, distressed assets, business opportunities within emerging industries such as the Metaverse and providing humanitarian efforts in over 185 countries

Why did it go up over 100%?

Dec. 07, 2021

One World Universe Inc.purchased two additional LAND within the Sandbox Virtual Metaverse world and is bidding on 3×3 parcels within the OpenSea NFT marketplace and plans to purchase no less than $100,000 worth of land this week alone.

5 Day

1 Day

Technical Analysis:

I like the vertical alot, metaverse is as hot as summer in Georgia! Furthermore, it’s almost up 1,000% in 13 trading days and up 100% in the last 5 trading days. I like the stock but I’m expecting a pullback, consolidation and then it may run again. We will keep an eye on this one! 

Winner #2:

Company Name: Dr. Foods, Inc.

Ticker: DRFS

Exchange: OTC

Website: https://dr-foods.net/en/#company 

Company Summary:

Dr. Foods, Inc. manufactures and distributes atmospheric water generators. The company designs and builds air-to-water appliances for residential and commercial drinking water applications based on patented, patent pending and proprietary technologies. Ambient Water was founded on December 19, 2005 and is headquartered in Tokyo, Japan.

Why did it go up over 100%?

No news, you’re guess is as good as ours. It has a tendency of good runs though.

3 month chart

5 Day

1 Day

Technical Analysis:

I like it! It just made a new 5 day high, broke out of a bearish trend and has a history of big runs! Put this on your watchlist and if you trade it, watch it like a hawk because it is volatile but it did provide 250+% gains just 5 months ago. This could be good for a quick 50% scalp. 

Well, you heard it here first, we do not confirm nor deny if we actually have a crystal ball! ALWAYS, remember, never try to catch a falling knife and trade with stop losses!

read more
Winners and Losers: PTPI, MTTR, and NRXP

Winners and Losers: PTPI, MTTR, and NRXP

Company Name: Petros Pharmaceuticals, Inc.

Ticker: PTPI

Exchange: NASDAQ

Website: https://www.petrospharma.com/

Industry: Health & Wellness 

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health and substance use disorders.

Why is it so Bullish?

Nov. 30, 2021 Petros Pharmaceuticals announces that it has entered into definitive agreements with the company’s largest investor and other existing investors, for the purchase and sale of 3,333,333 shares of Petros Pharmaceuticals’ common stock, at a purchase price of $3.00 per share. The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement. Petros Pharmaceuticals has also agreed to issue the investors unregistered warrants to acquire 2,500,000 shares of common stock at an exercise price of $3.50 per share, exercisable immediately and terminating 5 years after the date of issuance. The closing of the offering is expected to occur on or about December 2, 2021, subject to the satisfaction of customary closing conditions.

1 Day Chart 

Technical Summary

Based on the 5 day chart and 1 day chart, I would consider this a bearish trend and would AGAIN, wait for confirmations of a reversal before considering a purchase. NOTE, the 1 month looks interesting but again the short term charts are bearish. 

—————————————————————————————————–

Company Name: Matterport, Inc. 

Ticker: (MTTR)

Exchange: NASDAQ

Website: https://matterport.com/

Industry: Tech  

Company Summary:

Matterport, Inc. (Nasdaq: MTTR) is leading the digital transformation of the built world. Our groundbreaking spatial data platform turns buildings into data to make nearly every space more valuable and accessible. Millions of buildings in more than 150 countries have been transformed into immersive Matterport digital twins to improve every part of the building lifecycle from planning, construction, and operations to documentation, appraisal and marketing.

Why is it so Bullish?

On Nov. 23, 2021 Matterport announced another expansion of Matterport Capture Services™ On-Demand that adds 16 U.S. cities and 20 in Great Britain to its service map, increasing its regional coverage by 55 percent.

5 Day Chart

Technical Summary

Love this stock, it is very bullish and has great news announced today, see below.

Nov. 30, 2021, Matterport introduced Matterport BIM file, a new add-on service that dramatically decreases the time and costs of Building Information Modeling (BIM) for the Architecture, Engineering, and Construction (AEC) industry. Now included with a Matterport subscription, customers can quickly transform a Matterport digital twin captured by a compatible 3D camera into a ready-to-use BIM file at the click of a button. The output is delivered in days, ready to be brought into their BIM application of choice. This new service significantly expedites projects and reduces associated costs by up to 70%, eliminating the traditional manual process that requires considerable time and effort.

—————————————————————————————————–

Company Name: NRx Pharmaceuticals, Inc. 

Ticker: (NRXP)

Exchange: NASDAQ

Website: www.nrxpharma.com 

Industry: Medical

Company Summary:

NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. The Company is developing the BriLife® Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense. NRx is additionally developing ZYESAMI® (aviptadil) for patients with COVID-19, and has been granted Fast Track designation by the US Food and Drug Administration (FDA), and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022.

Why is it so Bullish?

Nov. 29, 2021 NRx Pharmaceuticals announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world’s most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.

1 Day Chart 

Technical Summary:

Another Covid stock, another overbought play that could be a winner but we need confirmation and understanding that it will be volatile. 

read more
SpotLite360 (CSE-LITE) made Huge gains since trading began, and could continue trending uphill.

SpotLite360 (CSE-LITE) made Huge gains since trading began, and could continue trending uphill.

Put LITE on your Watchlist NOW

3 Critical Events Have Made SpotLite360 the Darling of the Canadian Securities Exchange!

Here are the 3 critical events that could forever change supply chain technology!

  1. The chart is on fire!
  2. In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.” 2
  3. The FDA has proposed new traceability rules on critical tracking supply chain activities to combat the food fraud costs the industry $40 billion annually and the food-borne pathogens costs of $55.5 billion per year!

Company Name: SpotLite360

Ticker: CSE-LITE

Company Summary: SpotLite360 is a SaaS-based, enterprise software company leveraging IoT technologies, blockchain, & machine learning to deliver supply chain solutions which result in improved tracing, tracking, visibility, efficiency, collaboration & proof of sustainability claims for customers within pharmaceutical, healthcare & agriculture.

What do they do?

In lay terms, they develop software that improves tracing, tracking, visibility, efficiency, collaboration & proof of sustainability claims for customers within pharmaceutical, healthcare & agriculture. SpotLite360’s software allows companies to have a real-time view of inventory all over the world with a click of a mouse! Imagine if this software or software like it, was mandatory? The pandemic would have been way different, we would have had toilet paper, LOL!

#1. The trading for LITE is in an aggressive bullish trend with possibly no end in sight, producing 100% gains in a month!

 

SpotLite360-Chart

As you can see in this chart found above, this stock is absolutely trending extremely bullish. All indicators are positive and likely to continue in this upward trend line. In regards to the technicals, it is a STRONG BUY! 7

SpotLite360-Technicals

#2. In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.” 2

Take a look at this quote by an industry giant in the supply chain management:

Mike Crum, a professor and chair of supply chain management in Iowa State University’s Ivy College of Business was asked, Why is the government an important part of the supply chain?

“The government, through investments, financial incentives, regulations, and policies, greatly [affects] supply chain performance.” 3

It is clear, the writing is on the wall, whether you like it or not big brother is coming with mandates! The libertarians will be sounding the alarm that the police state is being ushered in, the Dems will be cheering the victory and the consumer will be tickled pink when essential goods will be available during the next crisis. As a trader, you have a rare opportunity to profit from big brother’s mandates.

In Big Pharma’s case it’s not if the government will mandate better supply chain technology, it’s when because we have the date!

In 2023, less than 2 years away, the FDA announced that they are making it mandatory to, “identify and trace certain prescription drugs as they are distributed throughout the U.S.”

Take a look at this excerpt from the FDA website!

The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. 2

Big brother is mandating that pharma companies must follow federal guidelines in regards to certain drugs, this is the reason why:

  • More than $1 billion in drug thefts annually
  • $236 billion in counterfeit drugs causing harm to the populace
  • 25% of vaccines damaged in transit, another result of Covid
  • 20% temperature sensitive drugs perish.

These mandates are looming, they are right around the corner and trillion dollar mega-companies will be scrambling to be compliant and SpotLite360 will be knocking on their door with possibly the best solution in the market with decades of experience!

Don’t believe me, this is an excerpt taken from the FDA website.

This will enhance FDA’s ability to help protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful. The system will also improve detection and removal of potentially dangerous drugs from the drug supply chain to protect U.S. consumers.2

SpotLite360-DSCSA

The above screen shot was taken from the FDA website.

If the big Pharma mandate by the federal government gets you excited, there are two mandates that will greatly impact SpotLite360! Take a look at this!

#3. The FDA has proposed new traceability rules on critical tracking supply chain activities to combat the food fraud costs the industry $40 billion annually and the food-borne pathogens costs of $55.5 billion per year!

Take a look at the following excerpt from the FDA’s website,

“The Drug Quality and Security Act (DQSA), was enacted by Congress on November 27, 2013. Title II of DQSA, the Drug Supply Chain Security Act (DSCSA), outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States.” 2

On July 13, 2020, the FDA released the Blueprint for the New Era of Smarter Food Safety. The blueprint outlines the FDA’s vision to enhance traceability, improve predictive analytics, respond more rapidly to outbreaks, address new business models, reduce contamination of food, and foster the development of stronger food safety cultures. Although the FSMA 204 rulemaking is limited to only certain foods, the blueprint identifies it as a foundational first step on the path to promoting tech-enabled end-to-end traceability for all foods. The proposed rule, when finalized, would establish a standardized approach to traceability recordkeeping, paving the way for industry to adopt, harmonize, and leverage more digital traceability systems in the future.

From the FDA’s website, “A modern, coordinated approach to traceability that can be used and understood throughout all stages of the food supply chain will go further to reduce foodborne illness, build consumer trust, and avoid overly-broad recalls.” 5

The federal government is pushing for these laws to ensure safety for its constituents and to respond to the majority who are interested in where their food comes from.

56% of shoppers want to know where their food comes from. 6

Our world, whether we like it or not, is headed towards: organic, lactose free, grass fed, grown in the USA, Kobe, farm raised, cruelty free and so on and so on. As the demand for thoses nomenclatures grow, the demand for the proof of those labels increases too.

56% of shoppers want to know where their food comes from. SpotLite360 (CSE-LITE) specializes in supply chain management via a SaaS platform that can meet the demands of those 56% that are demanding certificate of origin.

FDA is establishing these rules to tackle to avoid these problems:

  • Lack of visibility allows opportunities for product tampering and theft
  • 68% of consumers will pay more for products that are produced ethically and responsibly
  • As much as 60% of all food produced is wasted and never makes it to the consumer ($1 trillion)
  • Food-borne pathogens costs consumers $55.5 billion per year
  • Food fraud costs the industry $40 billion annually

SpotLite360 is catering to three verticals: agriculture, big pharma and healthcare. Of the three, two have or will have mandates to utilize the technology that SpotLite360 has developed. SpotLite360 will be funding its efforts to penetrate and control as much of the market share via a public offering. We are incredibly excited to share this information with you and highly encourage you to place SpotLite360 on your watchlist TODAY.

As A Quick Recap, the THREE Top Reasons to Put (CSE-LITE) on Your Watchlist Today!

  1. The chart is on fire!
  2. FDA announced that they are making it mandatory to identify and trace certain prescription drugs as they are distributed throughout the U.S., that could be worth TRILLION$!
  3. The FDA has proposed new traceability rules in regards to agriculture, people care about the efficacy of organic food!

1. https://uploads-ssl.webflow.com/603ffdbf0489872a5df6049e/605b6ae644f8e8b2989bff3c_spotliteeefinal.pdf

2. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-takes-steps-enhance-drug-supply-chain-security-setting-new-recommended-data-standards

3. https://www.futurity.org/supply-chain-us-government-2535692/

4. https://mitsloan.mit.edu/ideas-made-to-matter/post-pandemic-supply-chains-retool-a-new-abnormal

5. https://www.fda.gov/food/new-era-smarter-food-safety/tracking-and-tracing-food

6. https://www.spotlite360.com/investors

7. https://www.tradingview.com/symbols/CSE-LITE/

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, SpotLite360. Small Cap Exclusive has been hired by SpotLite360 for a period beginning on July 10, 2021 for 3 months to publicly disseminate information about SpotLite360 via website and email. We have been compensated $50,000 USD. We will update any changes to our compensation.

Read full disclaimer here.

read more